It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...

After hours: 7:59:33 pm GMT-5 ...

MIT professor in astronautics and director of the MIT Media Lab Dava Newman talked about “disruptive innovation” and how to ...

They are important niches to the scientists who can now solve previously unsolvable problems, but they may not constitute ...

Market report delivers crucial insights into the market's growth trajectory and the primary revenue drivers anticipated ...

Pharma giant Moderna (MRNA) is set to release its Q4 2024 results on February 14. MRNA stock has lost about 64% over the past ...

Karen Andersen, CFA, is a healthcare strategist for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She is r ...

It's unclear how he will impact biotech stocks. Evaluate the expected performance of Moderna (MRNA) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom ...

Moderna MRNA incurred a loss of $2.50 per share in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of ...

It's unclear how he will impact biotech stocks. Evaluate the expected performance of Moderna (MRNA) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...